Retatrutide (5 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Retatrutide (research code LY3437943) is a single-molecule triple agonist studied for its combined activity at the GLP-1, GIP and glucagon receptors. The values below are assembled purely for laboratory and educational reference — they describe how the material was handled and dosed in published trials, not a recommendation for use in humans or animals.

For a 5 mg vial, adding 1.0 mL of bacteriostatic water produces a concentration of 5 mg/mL (5,000 mcg/mL). At that fill, each unit on a U-100 insulin syringe (0.01 mL) carries 50 mcg of material, so 1 mg is equivalent to 20 units (0.20 mL). Because the vial is half the strength of a 10 mg fill, every weekly step draws roughly double the volume of the equivalent 10 mg step.

Standard (Gradual) Titration Schedule

The gradual schedule follows the slow dose-escalation arms used across the Phase 2 program, where weekly amounts were raised about every four weeks to keep gastrointestinal tolerability manageable.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 1.0 mL of bacteriostatic water and inject it slowly down the inner wall of the vial — never aim the stream directly at the powder pellet.
3. Swirl gently until the cake is fully dissolved. Do not shake; vigorous agitation can shear the peptide chain.
4. The finished solution should look clear and colourless. Label the vial with its concentration (5 mg/mL) and the date of reconstitution.
5. Keep the vial upright under refrigeration between draws and use a fresh sterile syringe for every withdrawal.

Advanced (Aggressive) Titration Schedule

The advanced schedule climbs to the 12 mg ceiling tested in Phase 2, where the top cohort logged the largest average weight reductions. It escalates faster through the mid-band and reaches three vials per dose at the highest step.

Supplies Needed

• Retatrutide vials (5 mg): ~10 vials for a 12-week gradual run to 6 mg; ~29 vials for a 24-week run to 8 mg; ~12 vials for a 12-week aggressive run.
• Insulin syringes (U-100, 1 mL): 12–36 for a 12-week schedule; 24–72 for 24 weeks (one fresh syringe per draw, and larger doses may split across two).
• Bacteriostatic water (10 mL): one bottle covers a ~10-vial run; three bottles for a 29-vial schedule.
• Alcohol swabs: ~75 for a 12-week run (one 100-count box); ~150 for 24 weeks (two boxes).

Protocol Overview

• Research goal: model metabolic weight-regulation through simultaneous GLP-1, GIP and glucagon receptor activation.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 2–8 mg standard, up to 12 mg in aggressive arms.
• Fill: 5 mg lyophilized, reconstituted to 5 mg/mL with 1 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 2 mg step and hold each level for about four weeks before escalating.
• Keep administration on a fixed weekly cadence — ideally the same day each week — for steady exposure modelling.
• Escalate only after tolerability has settled at the prior step.
• With a 5 mg/mL fill, plan ahead for the larger volumes at 6 mg and above, where doses pool material from more than one vial.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, shielded from light, where stability extends for up to about 24 months. Once reconstituted, refrigerate at 2–8 °C and use within roughly four weeks. Let refrigerated solution warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot any vial that will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• When a dose pools two or three vials, reconstitute each at the same 5 mg/mL fill so the math stays consistent.
• Split larger volumes across more than one syringe when they exceed a single barrel’s capacity.
• Document each draw — date, volume, vials used, remaining material — for reproducibility.

How Retatrutide Works

Retatrutide is a synthetic peptide engineered to act as a balanced agonist at three metabolic receptors at once: GLP-1 and GIP — both tied to glucose-dependent insulin signalling and appetite suppression — and the glucagon receptor, which is linked to raised energy expenditure and hepatic lipid handling. A fatty-acid moiety extends its circulating half-life to roughly six days, long enough to support once-weekly dosing in trials. This combined three-receptor profile is what separates it from single (GLP-1) and dual (GLP-1/GIP) agonists in the comparative literature, and it is associated with reduced calorie intake, greater satiety and increased fat oxidation.

Reported Benefits & Side Effects

Benefits observed in trials

• Average body-weight reduction of roughly 22–24% at 48 weeks in the highest-dose obesity cohort.
• HbA1c reductions of about 1.3–2.0% in the Type 2 diabetes study, with around 82% of participants reaching HbA1c at or below 6.5%.
• Improvements in blood pressure, LDL cholesterol, waist circumference and liver-fat markers.
• Resolution of hepatic steatosis in over 80% of the high-dose group, and essentially all high-dose participants achieving at least 5% weight loss.

Side effects reported

• Dose-dependent gastrointestinal effects — nausea, vomiting and diarrhoea — most frequent during escalation.
• Generally mild-to-moderate, transient, and reduced by slower four-week titration.
• No severe hypoglycaemia reported; overall tolerability comparable to other incretin agonists when titrated properly.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition as used in the published study designs.
• Combined resistance and aerobic activity to help preserve lean mass during weight reduction.
• Adequate sleep, stress management and hydration as standard trial controls.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let both dry fully.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Because higher 5 mg/mL doses run to larger volumes, split the draw across two sites when a single injection would be uncomfortable.
• Rotate sites systematically and discard sharps in an approved container.

References

Related Protocols